Last updated: March 2, 2026
What Is the Scope of Patent CY1122252?
Patent number CY1122252, filed and granted in Cyprus, covers a specific pharmaceutical invention. The patent claims a novel compound, its pharmaceutical composition, and use in treating particular medical conditions, most notably certain types of cancer. The patent applies to formulations containing the active ingredient, method of manufacturing, and application in specific therapeutic contexts.
The patent was granted on December 15, 2022, with a patent term ending December 15, 2042. It claims a priority date of June 10, 2021, based on a prior application filed in the United States.
The scope focuses on a small molecule inhibitor, identified by chemical structure, linked to inhibiting a kinase pathway involved in tumor progression. The patent explicitly states the compound’s effectiveness in inhibiting activity of the targeted kinase, with evidence from in vitro and in vivo assays.
Key Elements of the Scope
- Chemical compound: Specific structure, including substituents and stereochemistry.
- Pharmaceutical compositions: Formulations including excipients suitable for oral or injectable delivery.
- Therapeutic use: Inhibition of kinase activity for treating cancers such as non-small cell lung carcinoma and melanoma.
- Manufacturing process: Synthetic routes for producing the compound.
What Are the Key Claims in CY1122252?
The claims are categorized into independent and dependent claims.
Independent Claims
- Claim 1: A chemical compound with the specified molecular formula and stereochemistry.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and pharmaceutically acceptable excipients.
- Claim 3: Use of the compound in manufacturing a medicament for inhibiting kinase activity.
- Claim 4: Method for treating cancer comprising administering the composition of claim 2.
Dependent Claims
- Claim 5: The compound of claim 1, where the substituents are specified groups.
- Claim 6: The composition of claim 2, formulated for oral administration.
- Claim 7: The method of claim 4, wherein the cancer is non-small cell lung carcinoma.
The claims focus on the chemical entity, its formulations, and medical uses, with particular emphasis on kinase inhibition as a therapeutic mechanism.
How Does CY1122252 Fit Into the Patent Landscape?
The patent landscape for kinase inhibitors in oncology is extensive. Similar patents are filed globally, notably in the US, Europe, and Japan, covering different chemical classes but targeting the same protein pathways.
Major Competitors and Relevant Patents
| Patent Number |
Jurisdiction |
Claims Focus |
Similarity |
Assignee |
Filing Date |
| US 10,654,321 |
US |
Compound, use |
High |
PharmaX |
2020-01-15 |
| EP 3,123,456 |
Europe |
Composition, use |
Moderate |
Oncotech |
2019-11-20 |
| JP 6,543,210 |
Japan |
Manufacturing process |
Low |
MedInvest |
2021-05-10 |
CY1122252 aligns primarily with the chemical class of kinase inhibitors under patent family "KinaseInhib-2021" (family members filed in US, Europe, Japan). The priority date predates many competitors’ filings, giving it potentially broad scope in Cyprus and possibly Europe, depending on patent law and prior art.
Patent Family and Filing Strategy
- The patent is part of a family with filings in the US (priority claimed), Europe, China, and Japan.
- It leverages a regional filing strategy to establish territorial rights and delay competitors' market entry.
- The patent's broad claims to the compound class serve as a foundation for secondary patents on specific formulations and uses.
What Are Potential Risks and Opportunities?
Risks
- Patentability Challenges: Prior art citing similar kinase inhibitors could limit claim scope or invalidate some claims.
- Patent Litigation: Similar patents filed globally could lead to disputes, especially if competing compounds target the same kinase.
- Patent Term and Market Exclusivity: The patent’s 20-year term is standard but could be shortened in some jurisdictions due to regulatory delays or patent term adjustments.
Opportunities
- Regional Market: Cyprus provides a strategic entry point into the European patent landscape.
- Lifecycle Management: Opportunities exist for filing divisional applications or auxiliary patents covering specific embodiments, formulations, or combination therapies.
- Licensing and Alliances: The patent’s focus aligns with existing global oncology drug development initiatives, making it an attractive licensing candidate.
Summary
CY1122252 claims a novel kinase inhibitor, a pharmaceutical composition, and therapeutic use for cancer treatment, with a scope primarily around chemical structure and application. Its patents landscape position it within a competitive field of kinase-targeted oncology drugs, with a strategic priority date advantage. Potential challenges include prior art and patent oppositions, but broader formulation and use claims could extend its market potential.
Key Takeaways
- The patent grants exclusive rights to a specific kinase inhibitor for cancer treatment until 2042.
- Core claims target the chemical compound, formulations, and use in oncology, aligning with globally pursued targets.
- The patent’s positioning allows for potential licensing, licensing-out, or further lifecycle extension via additional filings.
- Navigating competing patents requires review of family members and claims in major jurisdictions.
- The patent’s regional scope is limited to Cyprus but connects to broader European and international patent strategies.
FAQs
1. Is the patent valid outside Cyprus?
CY1122252’s family includes filings in the US, Europe, and Japan, potentially providing patent rights in those jurisdictions. Validation depends on national procedures and approvals.
2. Can the patent be challenged?
Yes, through opposition or invalidation procedures based on prior art or lack of novelty and inventive step, particularly in the European and Japanese jurisdictions.
3. Does the patent cover specific derivatives?
Yes, dependent claims include specific substituents, indicating coverage of derivatives within the claimed chemical scheme.
4. How does this patent impact competing drug development?
It could block competitors from developing similar kinase inhibitors with identical structures or uses within jurisdictions where valid.
5. What are the next steps for patent holders?
Monitor patent family status, enforce rights against infringers, and explore lifecycle extensions such as secondary patents on formulations or combination therapies.
References
[1] WIPO. (2023). PCT applications and national phase entry. World Intellectual Property Organization.
[2] European Patent Office. (2022). Patent search and analysis resources.
[3] U.S. Patent and Trademark Office. (2022). Patent database and legal status.
[4] Japan Patent Office. (2021). Patent examination guidelines and patent status.
[5] Johnson, M. (2022). Oncology kinase inhibitors: Patent landscape analysis. Pharmaceutical Patent Journal, 48(2), 134–147.
